← Leaderboards
Zev A Wainberg
University Of California Los Angeles
$1,430,425
Attributed
$4,291,276
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,291,276 · 2
By mechanism
R01$4,291,276 · 2
Top collaborators
- Timothy R Donahue7 shared
- Caius Gabriel Radu7 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- David B Shackelford$6,228,155
- Jane C Deng$4,345,782
- David A. Nathanson$10,691,258
- Caius Gabriel Radu$8,088,566
- Tanya I Stoyanova$7,579,166
Others in their field
Other Emerging Leaders on “Programmed Cell Death Protein 1”
- James Dale Berry · Brigham And Women'S Hospital$9,673,541
- Eti Yoles · Immunobrain Checkpoint Inc.$5,749,685
- Chad V Pecot · Univ Of North Carolina Chapel Hill$5,572,660
- Kurt A Schalper · Emory University$5,549,801
- Yonathan Lissanu · University Of Tx Md Anderson Can Ctr$5,392,880
- Tina Garyantes · Linnaeus Therapeutics, Llc$5,000,000
Research focus
Programmed Cell Death Protein 1ProductionImmuneMetabolismPancreatic Cancer PatientsPhase Ia/Ib Clinical TrialClinical TrialsHuman ModelMediatingMass Spectrum AnalysisNucleotide MetabolismBioinformaticsPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma ModelAdenosineBiometryCell TypeExtracellularEvaluationImmunosuppressionMalignant Neoplasm Of PancreasMalignant NeoplasmsMouse ModelResistance
Grant awards (7)
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer$653,625
R01 · FY2025 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$585,317
R01 · FY2025 · CA
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer$653,452
R01 · FY2024 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$567,204
R01 · FY2024 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$590,100
R01 · FY2023 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$607,124
R01 · FY2022 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$634,454
R01 · FY2021 · CA